WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009132979) 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/132979    International Application No.:    PCT/EP2009/054637
Publication Date: 05.11.2009 International Filing Date: 20.04.2009
Chapter 2 Demand Filed:    11.11.2009    
IPC:
C07C 233/51 (2006.01), A61K 31/197 (2006.01), A61K 31/381 (2006.01), A61P 3/06 (2006.01), A61P 3/08 (2006.01), A61P 9/12 (2006.01), C07C 235/12 (2006.01), C07C 237/12 (2006.01), C07D 213/55 (2006.01), C07D 333/24 (2006.01)
Applicants: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 CH-4070 Basel (CH) (For All Designated States Except US).
ANDJELKOVIC, Mirjana [CH/CH]; (CH) (For US Only).
CECCARELLI, Simona M. [IT/CH]; (CH) (For US Only).
CHOMIENNE, Odile [FR/FR]; (FR) (For US Only).
MATTEI, Patrizio [CH/CH]; (CH) (For US Only)
Inventors: ANDJELKOVIC, Mirjana; (CH).
CECCARELLI, Simona M.; (CH).
CHOMIENNE, Odile; (FR).
MATTEI, Patrizio; (CH)
Agent: KLOSTERMEYER, Doerte; (CH)
Priority Data:
08155318.2 29.04.2008 EP
Title (EN) 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS
(FR) 4-TRIMÉTHYLAMMONIO-BUTYRATES UTILISÉS COMME INHIBITEURS DE CPT2
Abstract: front page image
(EN)This invention relates to novel 4-trimethylammoniobutyrates of the formula wherein A1, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.
(FR)Cette invention concerne de nouveaux 4-triméthylammonio-butyrates de formule (I), dans laquelle A1, R1, m et n sont tels que définis dans la description et dans les revendications, et leurs sels pharmaceutiquement acceptables. Ces composés inhibent l'activité de la carnitine palmitoyltransférase (CPT), notamment l'activité de CPT2, et peuvent être utilisés comme médicaments.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)